BridgeBio Oncology Therapeutics, Inc. GAAP EPS of -$0.49
Source: SeekingAlpha
2026-03-05 17:59:09 ET
More on BridgeBio Oncology Therapeutics, Inc.
- BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript
- BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least
- BridgeBio Oncology gains outperform rating from Raymond James
- Seeking Alpha’s Quant Rating on BridgeBio Oncology Therapeutics, Inc.
- Historical earnings data for BridgeBio Oncology Therapeutics, Inc.
Read the full article on Seeking Alpha
For further details see:
BridgeBio Oncology Therapeutics, Inc. GAAP EPS of -$0.49
BridgeBio Oncology Therapeutics Inc Com
NASDAQ: BBOT
BBOT Trading
-1.57% G/L:
$8.76 Last:
70,934 Volume:
$8.92 Open:
BBOT Latest News
March 18, 2026 04:05:00 pm
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
March 06, 2026 10:07:35 am
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
March 05, 2026 04:05:00 pm
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
